NASDAQ:ASND 9 December 2025

Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma shares fell 4.2% to around $197.25 in late trading December 9 after a Q3 earnings miss and a three-month FDA review delay for its key dwarfism drug. Volume was about 76% below average. The company posted Q3 revenue of €213.6 million but reported a net loss of €61 million, mainly from finance expenses. Despite the pullback, ASND remains near its 52-week high and up year-on-year.

9 December 2025

Earnings Reports·NASDAQ:ASND·Stock Market

Nevada Temporarily Bans Prediction Market Firm Kalshi Over Gaming License Dispute
March 20, 2026, 2:30 PM EDT. Kalshi, a prediction markets platform offering event-based contracts on sports, elections, and entertainment, was temporarily banned in Nevada by a 14-day restraining order from the First Judicial District Court. The ruling prohibits Kalshi from operating its derivatives exchange without a gaming license, marking the first state-level forced cessation for the company. The ban follows earlier Nevada cease-and-desist actions and precedes a likely extension through the legal case, said gaming attorney Daniel Wallach. The dispute comes amid mounting regulatory scrutiny nationally, including criminal charges from Arizona and ongoing battles in multiple states. Kalshi contends its sports contracts are financial swaps, not gambling, a view supported by the federal Commodity Futures Trading Commission, which claims jurisdiction over these markets. This case highlights tensions between state gambling laws and federally regulated prediction markets.